Vicebio Secures $100 Million Funding to Advance Multivalent Respiratory Virus Vaccines

Funding Amount:
Vicebio has secured $100 million in a Series B funding round to advance its multivalent respiratory virus vaccines.

Vaccine Development:
The funding will be used to advance the company's bivalent RSV and hMPV vaccine combo to Phase I trials and potentially through Phase II development.

Molecular Clamp Technology:
Vicebio is leveraging the Molecular Clamp technology to develop next-generation respiratory virus vaccines.

Announcement Date:
The funding was announced on September 23, 2024.

Company Background:
Vicebio was launched by Medicxi to advance the Molecular Clamp technology and develop innovative respiratory virus vaccines.